Clinical Research Studies: 

At Piedmont Eye Center we are dedicated to our patients and providing the latest technology available.  To do our part to ensure technology continues to advance, we are enrolled in multiple clinical trials.  If you would like more information about enrolling in one of our studies that apply to you, please contact our Research Coordinators, Susan Shelton (ext. 574), Michelle Wells (ext. 575) or Jennifer Frederick (ext.543) at 434.947.3984.  They will be happy to answer your questions.

Coming Soon! 

Title: A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND  PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINOPATHY (PAVILION)

 Sponsor: F. Hoffman-La Roche Ltd.

Purpose: To evaluate the efficacy, safety, and pharmacokinetics of Ranibizumab delivered via the Port Delivery System in patients with Diabetic Retinopathy.

Open Studies – Enrollment Open

Title: A Phase 1/2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular Age-related Macular Degeneration

Sponsor: Graybug Vision

Purpose: In this 2-part study, Part 1 is a multicenter, open-label, safety, tolerability, and systemic exposure evaluation to Sunitinib in escalating doses of a single IVT injection of GB-102, while Part 2 is a multicenter, double-masked, randomized (1:1:1), parallel‑group, safety, and efficacy evaluation of repeated IVT injections of 2 dose levels of GB‑102 compared with aflibercept.

Title:  GR40550 (PAGODA) – A Phase III, Multicenter, Randomized, Visual Assessor-Masked, Active-Comparator Study of the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System with Ranibizumab in Patients with Diabetic Macular Edema.

Sponsor: F. Hoffman-La Roche Ltd.

Purpose: Evaluate the efficacy, safety, and pharmacokinetics of the Port Delivery System with Ranibizumab in patients with Diabetic Macular Edema (DME).

Title: A Phase 3, Multi-Center, Randomized, Double Masked, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the Controlled Adverse Environmental Model for the Treatment of Dry Eye Syndrome

Sponsor: Mitotech, SA

Purpose: The objective of this study is to compare the safety and efficacy of SkQ1 ophthalmic solution to placebo for the treatment of the signs and symptoms of dry eye syndrome.

Title: A Phase 3, Multicenter, Randomized, Controlled, Double Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Sponsor: Oyster Point Pharma, Inc.

Purpose: The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease.

Title: A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye (ARISE-3)

Sponsor: ReGenTree, LLC

Purpose: The objective of this study is to compare the safety and efficacy of 0.1% RGN-259 Ophthalmic Solution to placebo for the treatment of the signs and symptoms of dry eye.

Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION

Sponsor: F. Hoffmann-La Roche Ltd

Purpose: This is a Phase III, multicenter, randomized, active comparator controlled, double-masked, parallel-group, 112-week study to investigate the efficacy, safety, durability, and pharmacokinetics of faricimab administered at up to 16-week intervals to treatment-naïve patients with nAMD.

Title: PROSPECTIVE, RANDOMIZED PHASE 3 STUDY COMPARING TWO MODELS OF A TRAVOPROST INTRAOCULAR IMPLANT TO TIMOLOL MALEATE OPHTHALMIC SOLUTION, USP, 0.5%

Sponsor: GLAUKOS CORPORATION

Purpose: To compare the safety and initial efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, USP, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Title: A Phase 3, Multi-center, Randomized, Double-Masked, Active Comparator−Controlled Study To Evaluate The Efficacy And Safety Of RO6867461 In Patients With Diabetic Macular Edema

Sponsor: F. Hoffmann-La Roche Ltd

Purpose: This study will evaluate the efficacy, safety, pharmacokinetics, and optimal treatment frequency of RO6867461 compared with aflibercept (Eylea®) monotherapy in patients with diabetic macular edema (DME). Specific objectives and corresponding endpoints for the study are outlined in the following table.

Title: Multi-Center, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration.

Sponsor: Chengdu Kanghong Biotechnology Co., Ltd.

Purpose: The purpose of this clinical study is to evaluate the efficacy and safety of 0.5 mg and 1.0 mg conbercept IVT injection compared with the vascular endothelial growth factor (VEGF) antagonist active control, aflibercept IVT injection (2.0 mg, Eylea®, Regeneron Pharmaceuticals, Inc.), in subjects with neovascular age-related macular degeneration (AMD).

Title: Comparison of Bimatoprost SR to Selective Laser Trabeculoplasty in Patients With Open-Angle Glaucoma or Ocular Hypertension

Sponsor: Allergan

Purpose: This study will evaluate the intraocular pressure-lowering effect and safety of Bimatoprost SR compared with selective laser trabeculoplasty in patients with open-angle glaucoma or ocular hypertension who are not adequately managed with topical IOP-lowering medication.

 

Open Studies- Closed Enrollment

Title: A CLINICAL COMPARISON OF TWO MARKETED EYE DROP PRODUCTS FOR THE REDUCTION OF OCULAR HYPEREMIA

Sponsor: Prestige Consumer Healthcare, Inc.

Purpose: To compare the results of two marketed eye drops for the reduction of red eyes.

Title: Efficacy and Safety of Bimatoprost Sustained-Release (SR) in Patients With Open-angle Glaucoma or Ocular Hypertension

Sponsor: Allergan

Purpose: A phase 3 study to evaluate the efficacy and safety of bimatoprost sustained-release (SR) in patients with open-angle glaucoma or ocular hypertension. The study includes a 12-month treatment period with an 8-month extended follow-up.     

Title:  Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

 Sponsor: Allergan

Purpose: Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration

Title: A MULTI-CENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE CONTROLLED, PARALLEL GROUP BIOEQUIVALENCE STUDY WITH CLINICAL ENDPOINT COMPARING BRINZOLAMIDE OPHTHALMIC SUSPENSION 1% of PERRIGO PHARMA INTERNATIONAL DAC to AZOPT® (BRINZOLAMIDE OPHTHALMIC SUSPENSION) 1% OF NOVARTIS PHARMACEUTICALS CORPORATION IN THE TREATMENT OF PRIMARY OPEN ANGLE GLAUCOMA OR OCULAR HYPERTENSION IN BOTH EYES. 

Sponsor: Perrigo

Purpose: The objective of the study is to demonstrate bioequivalence of brinzolamide ophthalmic suspension 1% (Perrigo Pharma International DAC) to Azopt® (brinzolamide ophthalmic suspension) 1% (Novartis Pharmaceutical Corporation) by comparing their efficacy and safety in the treatment of subjects with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OH) in both eyes.

What Our Patients Think

  • Ben Crosswhite / OWNER, CROSSWHITE FITNESS
    I couldn't recommend a better doctor, a better facility, and I'm so glad I did it.
  • Brenda Edson in front of a brick home
    Brenda Edson /
    "I could not have asked for a better experience at Piedmont Eye Center. From my very first visit, the staff was friendly, knowledgeable, and genuinely interested in me."
  • Bobby Moore /
    "I wish I would have done it many years ago now."
  • Bryan Mitchell outside of a football stadium
    Bryan Mitchell / ANALYST
    "My vision was the best it had been since I was a teen. I had my LASIK surgery performed almost 2 years ago, and it is as good today as it was then."
  • Caroline Trexler /
    "They ensured that the entire process from preliminary appointments to follow up visits went seamlessly – the perfect team that gave me perfect vision."
  • Charles / RETIRED COMMANDER , UNITED STATES NAVY
    "All and all, this has been a very pleasant and beneficial period for me. I recommend it highly for anyone in a similar situation.'
  • Cynthia Stewart standing outside
    Cynthia /
    "I feel almost like a new person It’s a wonderful feeling to wake up in the morning and be able to actually see across the room without fumbling for my glasses. "
  • Frances / RETIRED
    "Dr. Ceballos has always been very positive, clarifying everything medically, never leaving me in doubt and has always made me feel special and important."
  • Guy / RETIRED
    "The procedure was painless, and now I’m happy to say I only wear glasses to read. I have 20/20 vision in my left eye and 20/25 in my right. "
  • Janice Bloom standing in front of a tree
    Janice Bloom / ADMISSIONS DATABASE & COMMUNICATIONS DIRECTOR
    "Dr. Bowers and his staff treated me with the utmost in professional care, making sure I was comfortable throughout the entire process."
  • Barbara / RETIRED
    "The procedure was pain free and I am so pleased with the results. It was money well spent and it is unbelievable how clear and colorful everything is. I want to tell Dr. Bowers and his staff how grateful I am."
  • Jerome / RETIRED
    "Doctor Vogel has treated me professionally as has his staff. They have been caring and have answered my questions to my satisfaction."
  • Jon Dupin standing outside of a brick home
    Jon Dupin / PASTOR
    "LASIK is not just a medical advancement to me; it’s a miracle"
  • Josh Brewer / HUMANITARIAN AID
    "Because of Dr. Bowers and his team at Piedmont Eye Center, my everyday life is now a whole lot easier. "
  • Judy Bowman / MISSIONARY
    "My experience of having Laser Vision Correction was fantastic. Dr. Bowers and all his staff are so knowledgeable and professional, yet very personal, warm, caring, and friendly."
  • Lucy standing in a classroom
    Lucy /
    "Dr. Bowers and his team were very comforting. The next morning, I opened my eyes and was able to see the alarm clock across the room, which I was never able to see before. It was a miracle!"
  • Martha Ann / GRANDMOTHER
    "It is a wonderful feeling to have no RX lenses. I want to thank Dr. Bowers and the Surgery Center for the freedom I feel.”
  • Monica Shelton / Featured Patient
    "Everyone told me what they were going to be doing to me and what to expect every step of the way. My experience with Piedmont Eye Center and Dr. Bowers and the whole LASIK team was awesome!"
  • Adelia / RETIRED
    "God led me to Dr. Vogel. He is absolutely the most wonderful doctor in the world. Not only is he a great doctor, he is a great ‘people person’. You always feel safe with him."
  • Penny Abbot in front of a home
    Penny Abbott / Financial Consultant
    "From the great staff who helped me, to the simplicity of setting up my flexible spending account, to my complete satisfaction and enjoyment of having clear sight, this has been an easy process."
  • Sallie Bloom / SPECIAL EDUCATION TEACHER
    "The staff at Piedmont eased my nerves and the procedure was swift and smooth."
  • Sue Earsing and lasik eye surgery
    Sue / CHIROPRACTOR
    "I have always seen the world through glasses or contacts, so the sharpness of vision I have now was never there before."
  • Tim / NATIONAL ENDURO CHAMPION
    “Dr. Bowers not only met my expectations, he surpassed them. I had no idea that vision like this was possible. I no longer struggle in the shadows of a course- everything is clearer.”
  • Troy Doss
    Troy Doss / ASSISTANT PRINCIPAL AT JEFFERSON FOREST
    "Piedmont Eye Center takes care of the little things to make LASIK a comfortable process."
Read More Testimonials